Mazdutide combines GLP-1 and glucagon receptor agonism to target hepatic lipid clearance, basal energy expenditure, and systemic weight reduction in metabo
Read more Mazdutide and Hepatic Metabolism: Glucagon Co-Agonism, Liver Fat, and Energy Expenditure
Retatrutide in liver disease research shows remarkable reductions in hepatic fat. Clinical trials reveal triple GIP/GLP-1/glucagon receptor agonism resolve
Read more Retatrutide in Liver Disease Research: Evidence for Hepatic Fat Reduction
An evidence-based scientific overview of Mazdutide (IBI362), evaluating its dual GLP-1 and glucagon receptor co-agonism across in-vitro, preclinical, and h